Research programme: TAM receptor tyrosine kinase targeting therapeutics - Celldex TherapeuticsAlternative Names: TAM RTK - Celldex Therapeutics
Latest Information Update: 01 Dec 2016
At a glance
- Originator Salk Institute
- Developer Celldex Therapeutics Inc; Salk Institute
- Class Antibodies
- Mechanism of Action Axl receptor tyrosine kinase modulators; Receptor protein-tyrosine kinase modulators; TYRO3 receptor protein tyrosine kinase modulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Research Autoimmune disorders; Cancer; Infections